Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ferdinando Nicoletti | M | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 Jahre |
Gianni Garotta | M | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 Jahre |
Marco Donia | M | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Mai-Britt Zocca | M | 56 |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 8 Jahre |
Hans Schambye | M | 59 |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Dänemark | 5 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Yousef Al-Abed
- Persönliches Netzwerk